Retraction Note: High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience.

Arch Virol

Tropical Medicine Department, Tanta University, Tanta, Egypt.

Published: February 2024

Download full-text PDF	Source
http://dx.doi.org/10.1007/s00705-024-05990-z	DOI Listing

Publication Analysis

retraction note

note high

high success

success rates

rates sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin

sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin sofosbuvir/simeprevir/daclatasvir + ribavirin

sofosbuvir/simeprevir/daclatasvir + ribavirin retreatment

retreatment chronic

chronic hepatitis

hepatitis infection

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!